Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Dabigatran and Rivaroxaban vs Nadroparin in TKA
NCT01431456Phase 3Completed
- Sponsor
- Martini Ziekenhuis
- Start
- Sep 2013
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dabigatran and rivaroxaban in venous thromboembolism (VTE) (3 arms), sponsored by Martini Ziekenhuis. Primary endpoint: Incidence of bleeding events at 135 days. Started Sep 2013; status: completed.
02
Drugs
dabigatranrivaroxaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT01431456.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01431456.